It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The use of quantitative qRT-PCR assays for detection and quantification of late gametocyte stages has revealed the high transmission capacity of the human malaria parasite, Plasmodium falciparum. To understand how the parasite adjusts its transmission in response to in-host environmental conditions including antimalarials requires simultaneous quantification of early and late gametocytes. Here, we describe qRT-PCR assays that specifically detect and quantify early-stage P. falciparum gametocytes. The assays are based on expression of known early and late gametocyte genes and were developed using purified stage II and stage V gametocytes and tested in natural and controlled human infections. Genes pfpeg4 and pfg27 are specifically expressed at significant levels in early gametocytes with a limit of quantification of 190 and 390 gametocytes/mL, respectively. In infected volunteers, transcripts of pfpeg4 and pfg27 were detected shortly after the onset of blood stage infection. In natural infections, both early (pfpeg4/pfg27) and late gametocyte transcripts (pfs25) were detected in 71.2% of individuals, only early gametocyte transcripts in 12.6%, and only late gametocyte transcripts in 15.2%. The pfpeg4/pfg27 qRT-PCR assays are sensitive and specific for quantification of circulating sexually committed ring stages/early gametocytes and can be used to increase our understanding of epidemiological processes that modulate P. falciparum transmission.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Sultan Qaboos University, College of Medicine and Health Sciences, Muscat, Oman (GRID:grid.412846.d) (ISNI:0000 0001 0726 9430); Cardiff University, Division of Population Medicine, School of Medicine, College of Biomedical Sciences, Cardiff, UK (GRID:grid.5600.3) (ISNI:0000 0001 0807 5670)
2 Istituto Superiore di Sanità, Dipartimento di Malattie Infettive, Rome, Italy (GRID:grid.416651.1) (ISNI:0000 0000 9120 6856)
3 QIMR Berghofer Medical Research Institute and University of Queensland, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395)
4 University of Glasgow, Institute of Biodiversity, Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
5 University of Edinburgh, Institute of Immunology and Infection Research, School of Biological Sciences, Ashworth Laboratories, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
6 Sultan Qaboos University, College of Medicine and Health Sciences, Muscat, Oman (GRID:grid.412846.d) (ISNI:0000 0001 0726 9430)